Skip to main content
. Author manuscript; available in PMC: 2020 May 10.
Published in final edited form as: J Control Release. 2019 Mar 11;301:54–61. doi: 10.1016/j.jconrel.2019.03.008

Figure 2. Targeting of anti-ICAM-1/polystyrene nanoparticles (NPs) to the inflamed brain.

Figure 2.

Biodistribution of radiolabeled targeted-NPs (anti-ICAM-1/NPs or IgG/NPs as a control) 30 min after intravenous injection in control or TNFα-injured animals. (A) Blood, (B) lungs, (C) brain. *** (p<0.001, IgG vs anti-ICAM-1), *(p<0.05, IgG vs anti-ICAM-1), ### (p<0.001 anti-ICAM-1: Control vs TNFα). One-way ANOVA (Bonferroni post-hoc analysis). Mean±SD, controls n=6, TNFα n=3.